- Home
- PAXS vs STOK Comparison
PAXS vs STOK Comparison
Compare PAXS & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAXS
- STOK
- Stock Information
- Founded
- PAXS 2021
- STOK 2014
- Country
- PAXS United States
- STOK United States
- Employees
- PAXS N/A
- STOK N/A
- Industry
- PAXS Investment Managers
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- PAXS Finance
- STOK Health Care
- Exchange
- PAXS Nasdaq
- STOK Nasdaq
- Market Cap
- PAXS 703.9M
- STOK 721.4M
- IPO Year
- PAXS N/A
- STOK 2019
- Fundamental
- Price
- PAXS $15.92
- STOK $12.03
- Analyst Decision
- PAXS
- STOK Strong Buy
- Analyst Count
- PAXS 0
- STOK 7
- Target Price
- PAXS N/A
- STOK $21.40
- AVG Volume (30 Days)
- PAXS 195.0K
- STOK 405.8K
- Earning Date
- PAXS 01-01-0001
- STOK 11-05-2024
- Dividend Yield
- PAXS 11.72%
- STOK N/A
- EPS Growth
- PAXS N/A
- STOK N/A
- EPS
- PAXS N/A
- STOK N/A
- Revenue
- PAXS N/A
- STOK $16,742,999.00
- Revenue This Year
- PAXS N/A
- STOK $91.67
- Revenue Next Year
- PAXS N/A
- STOK $5.45
- P/E Ratio
- PAXS N/A
- STOK N/A
- Revenue Growth
- PAXS N/A
- STOK 81.08
- 52 Week Low
- PAXS $12.57
- STOK $3.77
- 52 Week High
- PAXS $15.93
- STOK $17.58
- Technical
- Relative Strength Index (RSI)
- PAXS 44.09
- STOK 39.51
- Support Level
- PAXS $15.58
- STOK $13.39
- Resistance Level
- PAXS $16.18
- STOK $14.72
- Average True Range (ATR)
- PAXS 0.25
- STOK 0.68
- MACD
- PAXS 0.01
- STOK 0.03
- Stochastic Oscillator
- PAXS 42.36
- STOK 7.24
About PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.